

Giorgia Bodini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6399299/publications.pdf>

Version: 2024-02-01

107
papers

2,065
citations

257450

24
h-index

265206

42
g-index

110
all docs

110
docs citations

110
times ranked

2682
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedance-pH Off Therapy. <i>American Journal of Gastroenterology</i> , 2010, 105, 1053-1061. | 0.4 | 190 |
| 2 | Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2013, 108, 1731-1742. | 0.4 | 187 |
| 3 | Proton pump inhibitors: use and misuse in the clinical setting. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1123-1134. | 3.1 | 112 |
| 4 | Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value?. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1423-1431. | 3.0 | 85 |
| 5 | Esophageal motility abnormalities in gastroesophageal reflux disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 86. | 1.1 | 68 |
| 6 | Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , 2020, 158, 515-526.e10. | 1.3 | 65 |
| 7 | Positive Glucose Breath Testing is More Prevalent in Patients With IBS-like Symptoms Compared With Controls of Similar Age and Gender Distribution. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 962-966. | 2.2 | 59 |
| 8 | Gastrointestinal involvement in systemic sclerosis. <i>Presse Medicale</i> , 2014, 43, e279-e291. | 1.9 | 59 |
| 9 | Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , 2019, 11, 2971. | 4.1 | 57 |
| 10 | Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. <i>American Journal of Gastroenterology</i> , 2016, 111, 1711-1717. | 0.4 | 55 |
| 11 | High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in vivo evaluation. <i>United European Gastroenterology Journal</i> , 2018, 6, 981-989. | 3.8 | 55 |
| 12 | The natural history of gastro-esophageal reflux disease: a comprehensive review. <i>Ecological Management and Restoration</i> , 2016, 30, 1-9. | 0.4 | 49 |
| 13 | The appropriate use of proton-pump inhibitors. <i>Minerva Medica</i> , 2018, 109, 386-399. | 0.9 | 46 |
| 14 | Vonoprazan fumarate for the management of acid-related diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1145-1152. | 1.8 | 43 |
| 15 | A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. <i>Nutrition</i> , 2019, 67-68, 110542. | 2.4 | 42 |
| 16 | Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. <i>Cancers</i> , 2020, 12, 1422. | 3.7 | 41 |
| 17 | A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1333-1343. | 1.8 | 39 |
| 18 | Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1579-1587. | 1.9 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1081-1086. | 1.5 | 36 |
| 20 | Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 493-501. | 3.7 | 30 |
| 21 | Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13056. | 3.4 | 30 |
| 22 | Epidemiology and natural history of gastroesophageal reflux disease. <i>Minerva Gastroenterology</i> , 2017, 63, 175-183. | 0.5 | 30 |
| 23 | The Lyon Consensus: Does It Differ From the Previous Ones?. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 311-321. | 2.4 | 26 |
| 24 | Esophageal testing: What we have so far. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2016, 7, 72. | 1.0 | 26 |
| 25 | Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the LÃ©mann Index. <i>Digestive and Liver Disease</i> , 2017, 49, 175-180. | 0.9 | 25 |
| 26 | Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. <i>Annals of Hepatology</i> , 2018, 17, 830-835. | 1.5 | 25 |
| 27 | Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IBD study. <i>Digestive and Liver Disease</i> , 2019, 51, 972-977. | 0.9 | 25 |
| 28 | A safety review of proton pump inhibitors to treat acid-related digestive diseases. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 785-794. | 2.4 | 24 |
| 29 | The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. <i>Journal of Gastroenterology</i> , 2019, 54, 261-270. | 5.1 | 24 |
| 30 | Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018, 50, 452-456. | 0.9 | 22 |
| 31 | Prevention of postoperative recurrence of Crohn's disease by Adalimumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 24, 1. | 1.6 | 21 |
| 32 | Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 437-449. | 3.1 | 21 |
| 33 | Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. <i>Scientific Reports</i> , 2021, 11, 10368. | 3.3 | 21 |
| 34 | Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 451-456. | 0.9 | 21 |
| 35 | Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease?. <i>Digestive and Liver Disease</i> , 2017, 49, 728-730. | 0.9 | 18 |
| 36 | Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. <i>Digestive and Liver Disease</i> , 2014, 46, 1043-1046. | 0.9 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1333-1341. | 3.3 | 17 |
| 38 | Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7. | 1.5 | 17 |
| 39 | Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020, 8, 1228-1235. | 3.8 | 16 |
| 40 | Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?. <i>Nutrients</i> , 2020, 12, 3363. | 4.1 | 16 |
| 41 | Concerns related to COVID-19 pandemic among patients with inflammatory bowel disease and its influence on patient management. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13233. | 3.4 | 15 |
| 42 | Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> in Crohn's disease: pharmacological and clinical implications. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 79-88. | 3.1 | 14 |
| 43 | Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease. <i>Digestive and Liver Disease</i> , 2019, 51, 640-647. | 0.9 | 14 |
| 44 | Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00177. | 2.5 | 14 |
| 45 | Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 99-104. | 2.3 | 14 |
| 46 | Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13002. | 3.4 | 13 |
| 47 | Optimal management of constipation associated with irritable bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 691. | 2.0 | 11 |
| 48 | Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. <i>Digestive and Liver Disease</i> , 2020, 52, 862-868. | 0.9 | 11 |
| 49 | Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. <i>United European Gastroenterology Journal</i> , 2021, 9, 507-516. | 3.8 | 11 |
| 50 | Advancements in the use of manometry and impedance testing for esophageal functional disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 425-435. | 3.0 | 10 |
| 51 | A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110314. | 3.2 | 10 |
| 52 | Granulocytes and monocytes apheresis induces upregulation of TGF- β 1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-DR. <i>Journal of Clinical Apheresis</i> , 2017, 32, 49-55. | 1.3 | 8 |
| 53 | Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13231. | 3.4 | 8 |
| 54 | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IBD study. <i>United European Gastroenterology Journal</i> , 2021, 9, 102-109. | 3.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study. <i>Digestive and Liver Disease</i> , 2017, 49, 997-1002. | 0.9 | 7 |
| 56 | Elevated Adherence to Vaccination Against SARS-CoV-2 Among Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2142-2143. | 1.3 | 7 |
| 57 | Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2015, 110, 472-473. | 0.4 | 6 |
| 58 | Treatment of early stage chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 519-524. | 3.1 | 6 |
| 59 | High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1220-1225. | 1.5 | 6 |
| 60 | Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2397-2402. | 2.3 | 6 |
| 61 | Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e134-e136. | 1.9 | 6 |
| 62 | Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 76-84. | 1.9 | 6 |
| 63 | Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV. <i>Annals of Hepatology</i> , 2020, 19, 222-225. | 1.5 | 5 |
| 64 | NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 972-973. | 3.7 | 4 |
| 65 | Gastroesophageal reflux disease: key messages for clinicians. <i>Minerva Gastroenterology</i> , 2022, 67, . | 0.5 | 4 |
| 66 | Gastro-esophageal reflux disease: Key messages for clinicians. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, , . | 2.2 | 4 |
| 67 | Letter: biological therapies are effective for prevention of postoperative Crohn's disease recurrence. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 322-322. | 3.7 | 3 |
| 68 | DOPO57 The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF- $\hat{\pm}$ levels and clinical outcome. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S42. | 1.3 | 3 |
| 69 | Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1240-1241. | 3.7 | 3 |
| 70 | Reproducibility and Transportability of the Absence of Incremental Infectious Adverse Events in Patients With Higher Anti-TNF Drug Levels. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e73-e73. | 1.9 | 3 |
| 71 | Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, . | 1.6 | 3 |
| 72 | Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 129-130. | 2.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 292-293. | 2.4 | 2 |
| 74 | Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1245-1245. | 3.7 | 2 |
| 75 | Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations. <i>Digestive and Liver Disease</i> , 2019, 51, 173-174. | 0.9 | 2 |
| 76 | Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. <i>Digestive and Liver Disease</i> , 2021, , . | 0.9 | 2 |
| 77 | The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. <i>Journal of Gastroenterology</i> , 2014, 49, 1362-1363. | 5.1 | 1 |
| 78 | Anti-Tumor Necrosis Factor Antibodies for Prevention of Crohn's Disease Recurrence After Surgery: More Than a Hope. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1856. | 4.4 | 1 |
| 79 | Tricyclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?. <i>American Journal of Gastroenterology</i> , 2016, 111, 1037-1038. | 0.4 | 1 |
| 80 | Tu2009 Does Lömann Index Reflect the Quality of Life in Crohn Disease Patients on Treatment With Biological Therapy?. <i>Gastroenterology</i> , 2016, 150, S1004-S1005. | 1.3 | 1 |
| 81 | A Nodule, is a Nodule, is a Nodule: May Alpha-Fetoprotein Make the Difference?. <i>American Journal of Gastroenterology</i> , 2017, 112, 1340. | 0.4 | 1 |
| 82 | Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: The perfect storm. <i>Liver International</i> , 2018, 38, 2101-2101. | 3.9 | 1 |
| 83 | A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients. <i>American Journal of Gastroenterology</i> , 2019, 114, 364-365. | 0.4 | 1 |
| 84 | P576 Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn's disease patients treated with anti-TNF: a prospective multi-centre study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S402-S403. | 1.3 | 1 |
| 85 | Applicability of Parameters for the Noninvasive Diagnosis of Esophageal Varices Needing Treatment to Hepatitis C Virus-Cured Patients. <i>Clinical Infectious Diseases</i> , 2021, 72, 1862-1863. | 5.8 | 1 |
| 86 | Letter: predictive factors for treatment discontinuation in IBD—anti-TNF trough levels and anti-drug antibodies. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 536-537. | 3.7 | 1 |
| 87 | Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2020, 58, 208-213. | 0.6 | 1 |
| 88 | Development and Validation of a Multi-marker Serum Test for the Assessment of Mucosal Healing in Crohn's Disease Patients. <i>American Journal of Gastroenterology</i> , 2017, 112, S324. | 0.4 | 1 |
| 89 | Letter: vedolizumab or a second anti-TNF—no difference in efficacy for primary biologic failures with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1044-1045. | 3.7 | 1 |
| 90 | Prevention of Crohn's Disease Recurrence After Surgery: On the Road to Recovery. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1406. | 4.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Sa1933 Biological Therapy Is Able to Halt Crohn's Disease Progression: A Prospective, Long Term Study Using the LÃ©Mann Index. <i>Gastroenterology</i> , 2016, 150, S408. | 1.3 | 0 |
| 92 | Sa1877 Do Ulcerative Colitis Patients Treated With Corticosteroids at Diagnosis Really Have a More Aggressive Disease Course?. <i>Gastroenterology</i> , 2016, 150, S388. | 1.3 | 0 |
| 93 | 173 Esophagogastric Junction Morphology Assessment by High Resolution Manometry and Its Relationship With Gastroesophageal Reflux Disease in Obese Patients Candidate to Bariatric Surgery. <i>Gastroenterology</i> , 2016, 150, S44. | 1.3 | 0 |
| 94 | Proximal Esophageal Baseline Impedance Levels are Able to Discriminate between Scleroderma Patients with and without Esophageal Involvement. <i>Gastroenterology</i> , 2017, 152, S654. | 1.3 | 0 |
| 95 | Different Proton Pump Inhibitors are Equally Effective in Inducing Endoscopic and Histologic Remission in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. <i>Gastroenterology</i> , 2017, 152, S860-S861. | 1.3 | 0 |
| 96 | Proton Pump Inhibitor Therapy Improves Esophageal Symptoms by Restoring a Normal Esophageal Peristalsis in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. <i>Gastroenterology</i> , 2017, 152, S860. | 1.3 | 0 |
| 97 | OC.09.5 LONG TERM COLECTOMY RATE IN ACUTE SEVERE ULCERATIVE COLITIS. AN ITALIAN MULTICENTER IG-IBD STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e102. | 0.9 | 0 |
| 98 | OC.12.1 REAL-LIFE EFFECTIVENESS OF USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CONCOMITANT PSORIASIS OR PSORIATIC ARTHRITIS: AN IG-IBD STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e109. | 0.9 | 0 |
| 99 | P.07.4 HIGH ANTI-TNF ALFA DRUGS TROUGH LEVELS ARE NOT ASSOCIATED WITH THE OCCURRENCE OF ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <i>Digestive and Liver Disease</i> , 2019, 51, e223. | 0.9 | 0 |
| 100 | P541 Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S384-S385. | 1.3 | 0 |
| 101 | Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand. <i>Liver Cancer</i> , 2019, 8, 524-526. | 7.7 | 0 |
| 102 | Regression of Fibrosis After Direct-acting Antivirals Treatment of Patients with Hepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 546. | 0.9 | 0 |
| 103 | Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice. <i>Digestive and Liver Disease</i> , 2020, 52, 792-793. | 0.9 | 0 |
| 104 | Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 410. | 4.4 | 0 |
| 105 | Liver Stiffness Improvement Is Associated With Amelioration of Indirect Parameters of Portal Hypertension One Year After Sustained Virological Response to Direct Acting Antivirals in Chronic Hepatitis C Patients. <i>American Journal of Gastroenterology</i> , 2018, 113, S577. | 0.4 | 0 |
| 106 | Study on the impact of Sexually Transmitted Infections (STIs) on quality of life, mood and sexual function. <i>Italian Journal of Dermatology and Venereology</i> , 2020, , . | 0.2 | 0 |
| 107 | Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment. <i>Gastrointestinal Disorders</i> , 2022, 4, 77-83. | 0.8 | 0 |